KR20180025993A - 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 - Google Patents

배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20180025993A
KR20180025993A KR1020187005757A KR20187005757A KR20180025993A KR 20180025993 A KR20180025993 A KR 20180025993A KR 1020187005757 A KR1020187005757 A KR 1020187005757A KR 20187005757 A KR20187005757 A KR 20187005757A KR 20180025993 A KR20180025993 A KR 20180025993A
Authority
KR
South Korea
Prior art keywords
release
analgesic
pharmaceutical composition
extended
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187005757A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 딜
Original Assignee
웰즐리 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,332 external-priority patent/US20120135050A1/en
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by 웰즐리 파마슈티컬스 엘엘씨 filed Critical 웰즐리 파마슈티컬스 엘엘씨
Publication of KR20180025993A publication Critical patent/KR20180025993A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Guiding Agricultural Machines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020187005757A 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 Abandoned KR20180025993A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/343,332 US20120135050A1 (en) 2010-07-08 2012-01-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/343,332 2012-01-04
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2012/051888 WO2013103390A1 (en) 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018677A Division KR20140108675A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20180025993A true KR20180025993A (ko) 2018-03-09

Family

ID=48745355

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187005757A Abandoned KR20180025993A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
KR1020147018677A Ceased KR20140108675A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147018677A Ceased KR20140108675A (ko) 2012-01-04 2012-08-22 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법

Country Status (13)

Country Link
US (3) US8685453B2 (enExample)
JP (4) JP2015503583A (enExample)
KR (2) KR20180025993A (enExample)
AU (2) AU2012363789B2 (enExample)
BR (1) BR112014016661A8 (enExample)
CA (1) CA2856677A1 (enExample)
IL (1) IL232715A0 (enExample)
MX (1) MX2014008283A (enExample)
MY (1) MY173582A (enExample)
RU (1) RU2603471C2 (enExample)
SG (1) SG11201500407XA (enExample)
WO (1) WO2013103390A1 (enExample)
ZA (1) ZA201404606B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CN103796669B (zh) 2011-07-18 2016-11-09 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
CA2868073C (en) * 2012-03-30 2020-12-29 Givaudan S.A. N-acyl proline derivatives as food flavouring compounds
RU2016152226A (ru) * 2014-06-06 2018-07-09 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
EP3197441A4 (en) * 2014-09-24 2018-05-23 Wellesley Pharmaceuticals, LLC Pharmaceutical formulation for reducing bladder spasms and method of use thereof
JP2018526441A (ja) * 2015-09-01 2018-09-13 ウェルズリー ファーマスーティカルズ、エルエルシー 延長、遅延および即時放出製剤、ならびにその製造および使用方法
EP3344241A4 (en) * 2015-09-01 2019-04-03 Wellesley Pharmaceuticals, LLC FORMULATIONS WITH DELAYED RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
SG11201805527QA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040006887A (ko) * 2002-07-16 2004-01-24 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
KR20050111784A (ko) * 2003-03-21 2005-11-28 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR20070027761A (ko) * 2004-08-20 2007-03-09 훼링 비.브이. 항이뇨제로서 유용한 헤테로사이클 축합 화합물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE169498T1 (de) * 1991-09-06 1998-08-15 Mcneilab Inc Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
JP3660979B2 (ja) * 2000-09-05 2005-06-15 国立大学法人金沢大学 夜間頻尿症の治療剤、夜間頻尿症の予防剤
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
JPWO2003043655A1 (ja) * 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
CN1633283A (zh) * 2002-02-19 2005-06-29 法玛西雅公司 环加氧酶抑制剂和抗蕈毒碱试剂用于治疗失禁的用途
US7582651B2 (en) * 2002-07-11 2009-09-01 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
WO2006059237A1 (en) * 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
EA200800370A1 (ru) * 2005-07-20 2008-06-30 Панацея Биотек Лтд. Новая фармацевтическая лекарственная форма ингибитора фермента циклооксигеназы с модифицированным высвобождением
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
BRPI0714915A2 (pt) 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
EP2630955B1 (en) * 2007-08-15 2021-09-22 Johnson & Johnson Consumer Inc. Immediate release and sustained release ibuprofen dosing regimen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
JP2018016869A (ja) * 2016-07-29 2018-02-01 日立化成株式会社 アルミニウム系多孔質体及びその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040006887A (ko) * 2002-07-16 2004-01-24 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
KR20050111784A (ko) * 2003-03-21 2005-11-28 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR20070027761A (ko) * 2004-08-20 2007-03-09 훼링 비.브이. 항이뇨제로서 유용한 헤테로사이클 축합 화합물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
American Journal of Epidemiology, 173(9), 2011.5., pp.1022-1031 1부. *

Also Published As

Publication number Publication date
MX2014008283A (es) 2015-03-03
JP2015503583A (ja) 2015-02-02
ZA201404606B (en) 2015-11-25
AU2017203418A1 (en) 2017-06-08
AU2012363789A1 (en) 2014-07-17
CA2856677A1 (en) 2013-07-11
BR112014016661A8 (pt) 2017-07-04
IL232715A0 (en) 2014-07-31
US20140154320A1 (en) 2014-06-05
BR112014016661A2 (pt) 2017-06-13
NZ721818A (en) 2017-07-28
US8685453B2 (en) 2014-04-01
NZ732149A (en) 2018-11-30
AU2012363789A2 (en) 2014-07-24
US20130216620A1 (en) 2013-08-22
JP2018087217A (ja) 2018-06-07
KR20140108675A (ko) 2014-09-12
AU2017203418B2 (en) 2019-01-17
JP2017031172A (ja) 2017-02-09
NZ626619A (en) 2017-03-31
SG11201500407XA (en) 2015-03-30
MY173582A (en) 2020-02-04
JP2020037575A (ja) 2020-03-12
US20150272968A1 (en) 2015-10-01
RU2014131285A (ru) 2016-02-20
AU2012363789B2 (en) 2017-04-13
RU2603471C2 (ru) 2016-11-27
WO2013103390A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
KR20180025993A (ko) 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
US8236857B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8445015B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
KR20140108674A (ko) 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법
KR20140134333A (ko) 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법
AU2018208765A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK1248549A1 (zh) 用於缓解尿频的延长释放制剂及其使用方法
KR20180054655A (ko) 연장, 지연 및 즉시 방출 제형 제조 방법 및 용도
KR20180066112A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
EP2612663A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法
KR20180094512A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
KR20180066113A (ko) 배뇨 빈도 감소용 조성물, 제조 방법 및 용도
KR20180054656A (ko) 지연-방출 제형, 제조 방법 및 용도
HK1187241A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180227

Application number text: 1020147018677

Filing date: 20140704

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180327

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180615

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181219

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181219

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20180615

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190218

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180814

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180327

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190813

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190725

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190218

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180814

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180327

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PC1904 Unpaid initial registration fee